Allied Corp., a Health-related Cannabis Enterprise, indicators Master Solutions Agreement with Carmel – University of Haifa, Israel for Pre-clinical Pharmaceutical Improvement of a PTSD Drug.


KELOWNA, British Columbia, Oct. 28, 2019 (GLOBE NEWSWIRE) — Allied Corp. (“Allied”) (OTCQB: ALID), an international healthcare cannabis business focused on developing and offering targeted cannabinoid well being options, is pleased to announce it has entered into a Master Solutions Agreement with the University of Haifa, Israel by means of their wholly owned commercialization subsidiary: Carmel – Haifa University Financial Corporation Ltd. (“Haifa”). This globe-class academic study center offers Allied access to a proprietary pre-clinical animal model that is owned by Carmel. Especially, Allied will engage with this proprietary animal model for the purposes of specialized pharmaceutical cannabinoid study and pharmaceutical item improvement.

Via this agreement, Allied now has access to Haifa’s major-edge facilities, proprietary animal model, pharmaceutical improvement, academic laboratory and related scientists and investigators. This will allow Allied to conduct the pre-clinical phase of the improvement of a proprietary pharmaceutical item for which Allied has patent-pending status. This pharmaceutical item (“AC001”) targets the remedy of Post-Traumatic Anxiety Disorder and connected mental well being circumstances. Following the completion of the pre-clinical study phase, Allied intends to bring AC001 via human clinical trials. Following this, Allied intends to then seek a international commercialization partnership via a licensing deal for item AC001 with a huge pharma international commercialization companion.

“Building upon Allied’s existing patent-pending position, and as portion of Allied’s Intellectual House and Pharma Improvement (IP&ampPD) Approach, we are excited to start pre-clinical testing of our novel formulations. This is outlined in the parameters of our current United States Provisional Patent Application for Cannabinoid and Terpenoid Pharmaceutical Compositions and Strategies for Treating Post-Traumatic Anxiety Disorder (PTSD)” says David Weinkauf, VP-Pharma Improvement for Allied Corp. “This is the initial significant step towards Allied bringing an academically validated pharmaceutical item to these who will need it most these persons about the globe who have provided of themselves to serve their nation and are now suffering with PTSD”.

Extra info about Allied Corp. can be identified at www.allied.well being.

On behalf of the Board,

Calum Hughes
Chief Executive Officer

About Carmel – Haifa University Financial Corporation Ltd.
Carmel-Haifa University Financial Corporation Ltd. serves as the commercialization and small business arm of the University of Haifa and is accountable for guarding and commercializing its intellectual home. Carmel-Haifa collaborates with several partners and establishes ventures, corporations and funds with the target of maximizing the small business possible of commercializing study and expertise created at the University.

Extra info about Carmel – Haifa can be identified at

About Allied Corp.
Allied Corp. is an international cannabis business with a mission to aid persons suffering from Post-Traumatic Anxiety Disorder (PTSD) by researching, developing and making targeted cannabinoid well being options. Allied Corp. utilizes an proof-informed scientific strategy to make this mission achievable, via cutting-edge pharmaceutical study and improvement, revolutionary plant-primarily based production and distinctive improvement of therapeutic solutions.

Media Speak to:
[email protected]

Investor Relations:
Anthony Zelen
[email protected]

Forward-Searching Statements:
This news release may well include “forward-seeking statements” inside the which means of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements relate to future events or future overall performance. Statements which are not purely historical are forward-seeking statements and involve any statements concerning beliefs, plans, outlook, expectations or intentions concerning the future like words or phrases such as “anticipate”, “become”, “objective”, “may”, “will”, “might”, “should”, “could”, “can”, “intend”, “expect”, “believe”, “estimate”, “predict”, “potential”, “plan”, “is created to”, “project”, “continue”, or related expressions recommend future outcomes or the adverse thereof or related variations. Such forward-seeking statements  involve, but are not restricted to, that the Enterprise will practical experience development and will be in a position to expand globally.. We are also topic to several further dangers as described in our SEC filings at

Forward-seeking statements are primarily based on management’s existing expectations and may well materially differ from actual benefits.  Additional, such forward-seeking statements and are topic to dangers and uncertainties that could negatively impact our small business, operating benefits, economic situation and stock cost.

We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-seeking statements contained herein to reflect any alter in our expectations or any alter in events, circumstances or situations on which any such statement is primarily based, except as expected by law.

This write-up was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s major agency and digital economic media network committed to the burgeoning CBD and legal cannabis industries. Contact +1 (833) 420-CNFN for extra info.

About Ryan Allway

Mr. Allway has more than a decade of practical experience in the economic markets as each a private investor and economic journalist. He has been actively involved in the cannabis market considering the fact that its inception, covering public and private corporations.


Latest posts